Protalix BioTherapeutics (PLX) FCF Margin (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly FCF Margin of 63.0% for Q1 2026, up 11724.0% year-over-year from N/an in Q1 2025, and up 98.46% quarter-over-quarter from 31.75% in Q4 2025.
Protalix BioTherapeutics (PLX) FCF Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 63.0% for Q1 2026.
- In Q1 2026, FCF Margin rose 11724.0% year-over-year to 63.0%; the TTM figure through Mar 2026 stood at 18.84% (up 2241.0% YoY), while the FY2025 annual figure was 23.44%, down 3728.0% from the prior year.
- FCF Margin for Q1 2026 stood at 63.0%, up from 31.75% in the prior quarter.
- The five-year high for FCF Margin was 107.84% in Q1 2024, with the low at 84.2% in Q2 2022.
- The 5-year median for FCF Margin is 26.61% (2024), against an average of 9.98%.
- The sharpest annual moves came in 2022 and 2024: FCF Margin tumbled 18121 bps in 2022, then soared 14251 bps in 2024.
- Protalix BioTherapeutics' FCF Margin stood at 29.58% in 2022, then surged by 225 bps to 37.0% in 2023, then plunged by 47 bps to 19.57% in 2024, then soared by 62 bps to 31.75% in 2025, then surged by 98 bps to 63.0% in 2026.
- Business Quant data shows PLX's FCF Margin at 63.0% in Q1 2026, 31.75% in Q4 2025, and 25.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 70.82% |
| 10 | Protalix BioTherapeutics | 192.37 Mn | 151.71 Mn | 12.13 Mn | -55.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.25% |
| Mar 31, 2026 | 63.00% |
| Dec 31, 2025 | 31.75% |
| Sep 30, 2025 | -25.71% |
| Jun 30, 2025 | -33.11% |
| Mar 31, 2025 | -54.24% |
| Dec 31, 2024 | 19.57% |
| Sep 30, 2024 | 18.76% |
| Jun 30, 2024 | -26.61% |
| Mar 31, 2024 | 107.84% |
| Dec 31, 2023 | 37.00% |
| Sep 30, 2023 | -70.90% |
| Jun 30, 2023 | 13.82% |
| Mar 31, 2023 | -34.67% |
| Dec 31, 2022 | -29.58% |
| Sep 30, 2022 | -65.77% |
| Jun 30, 2022 | -84.20% |
| Mar 31, 2022 | -36.66% |
| Dec 31, 2021 | -48.78% |
| Sep 30, 2021 | -18.45% |